| 前收市價 | 58.00 |
| 開市 | 57.72 |
| 買盤 | 58.36 x 200 |
| 賣出價 | 58.60 x 100 |
| 今日波幅 | 56.10 - 58.87 |
| 52 週波幅 | 42.21 - 76.98 |
| 成交量 | |
| 平均成交量 | 508,103 |
| 市值 | 2.923B |
| Beta 值 (5 年，每月) | 0.89 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.41 |
| 業績公佈日 | 2024年5月08日 - 2024年5月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 86.07 |
InvestorPlaceBillionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Since Bill Gates left his position with Microsoft (NASDAQ:MSFT) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest. Gates was one of the loudest voices during the Covid-19 pandemic for providing therapeutics to poor countries and elsewhere. His Bill and Melinda Gates Foundation used its clout to influence response to the disease by governments around the world. The Foundation also gave more than $1 billion to the World Health Organiza
Insider MonkeyImmunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript February 28, 2024 Immunocore Holdings plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the Immunocore Fourth Quarter Financial Results Conference Call. At this time, all participants are […]
ZacksSarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
